Streamline Your Pathway To IND With A Rapid Tox Approach

mAbs, bispecifics, and other antibody-derived therapeutics continue to take the pharmaceutical industry by storm thanks to their ability to offer targeted treatments for cancer and autoimmune disorders. To accommodate faster pathways to patients, drug developers and CDMOs are working on innovations that enable speed to IND filing and first-in-human (FIH) studies, including producing material for toxicology (tox) studies as rapidly as possible. By procuring tox material sooner, developers can conduct tox studies earlier, enabling a streamlined runway to IND submission.

In a recent webinar on how to accelerate tox material generation to conduct earlier tox studies, a group of Lonza experts sat down to discuss the strategies Lonza has designed to support customers in pursuit of a faster timeline to IND. Access the full article to read their answers to audience questions on how to minimize bottlenecks with Lonza’s Pool for Tox and rapid tox offerings and mitigate risk along the way.